Clinical trials: Acute Ischemic Stroke
Acute Ischemic Stroke
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions…
- Trial name
- NUVISTA (NCT05390580)
- Testing
- transcutaneous auricular vagal nerve stimulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Ischemic Stroke
Argatroban Stroke Treatment - A Pilot Safety Study
Is the combination of low doses of argatroban in combination with rt-PA safe, and does it increase recanalization in patients with acute ischemic stroke.
- Trial name
- NCT00268762
- Testing
- argatroban
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Ischemic Stroke, Stroke
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome…
- Conditions
- Ischemic Stroke, Stroke, Brain Infarction
- Trial name
- CLEAR-ER (NCT00894803)
- Testing
- Eptifibatide, rt-PA
- Where
- 20 sites in United States
- Volunteers
- 126 people
- Sponsor
- University of Cincinnati
Stroke, Acute Ischemic Stroke
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
This study is a multi-center, multi-phase, multi-cohort, prospective, randomized, open, blinded endpoint (PROBE), non-significant risk (NSR) device study including up to 420 evaluable subjects measured with the study device(s)…
- Trial name
- VOICE (NCT05547412)
- Testing
- NovaGuide 2 Intelligent Ultrasound System
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NeuraSignal Inc dba NovaSignal
Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro…
- Trial name
- TREVO (NCT01088672)
- Testing
- Mechanical Thrombectomy
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Stryker Neurovascular
Ischemic Stroke
Efficacy and Safety of Mexidol® in Stroke Therapy
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo.
- Trial name
- MIR (NCT06437626)
- Testing
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Where
- 17 sites in Kazakhstan, Russia and 1 more
- Volunteers
- 304 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Enoxaparin and/or Minocycline in Acute Stroke
The purpose of this study is to investigate whether enoxaparin, minocycline, or both medications in combination may help in recovery from acute stroke.
- Trial name
- NCT00836355
- Testing
- Enoxaparin, Minocycline
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Acute Non-cardioembolic Ischemic Stroke
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non…
- Trial name
- PACIFIC-STROKE (NCT04304508)
- Testing
- BAY2433334
- Where
- 197 sites in United States, Australia and 21 more
- Volunteers
- 1,808 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Multi-arm Optimization of Stroke Thrombolysis
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results…
- Trial name
- MOST (NCT03735979)
- Testing
- Argatroban, Eptifibatide
- Where
- 61 sites in United States
- Volunteers
- 514 people
- Sponsor
- Washington University School of Medicine
Acute Ischemic Stroke, Biofeedback
Effects of Biofeedback in Patients With Acute Cerebral Infarction
The major aim of this study is to investigate the effects of biofeedback assisted abdominal breathing training on improving the psychological and physiological distress in patients with ACI.
- Conditions
- Acute Ischemic Stroke, Biofeedback, Autonomic Dysfunction, Cognitive Function, Psychological Distress
- Trial name
- NCT03516227
- Testing
- heart rate variability biofeedback
- Volunteers
- 40 people
- Sponsor
- National Defense Medical Center, Taiwan
Acute Ischemic Stroke
Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours.
- Trial name
- NCT03198715
- Testing
- DS1040b
- Where
- 20 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Acute Ischemic Stroke
Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System
Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case…
- Trial name
- NITE1 (NCT04881162)
- Testing
- NOVIS Transcarotid Neuroprotection System (NPS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Silk Road Medical
Intracerebral Hemorrhage, Acute Ischemic Stroke
Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage
This study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain.
- Trial name
- BEACH (NCT04027049)
- Testing
- Supine cycle ergometry of the lower extremities
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Stroke, Acute
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours.
- Trial name
- TEMPO-2 (NCT02398656)
- Testing
- Tenecteplase, Antiplatelet treatment
- Where
- 61 sites in Australia, Austria and 8 more
- Volunteers
- 1,274 people
- Sponsor
- University of Calgary
Stroke, Acute
The Role of Hyperoxia in Acute Ischemic Stroke
This study is being conducted to evaluate the potential therapeutic role of hyperoxia when applied in the immediate ischemic period following a stroke in the controlled Emergency Department setting.
- Trial name
- NCT03904017
- Testing
- Oxygen
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Stroke, Hyperglycemia
Glucose Regulation in Acute Stroke Patients (GRASP) Study
The purpose of this study is to assess the feasibility, safety and preliminary efficacy of the use of insulin infusions as treatment for hyperglycemic acute ischemic stroke patients.
- Trial name
- NCT00282867
- Testing
- IV glucose insulin and potassium, GIK, standard care
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Virginia
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome, TIA
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
- Conditions
- Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest
- Trial name
- NCT03605693
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University